Company intelligence / Profile preview

Corsair Management

Sunnyvale or Newark* (*recent press releases list both cities), California, United Statescorsairmanagement.com ↗

Ownership: Private
Development stage: Other

Overview

Corsair Pharma has completed preclinical studies for its lead program, a once-daily transdermal patch delivering a treprostinil prodrug for PAH. The company demonstrated steady and therapeutically meaningful blood levels in animal models with acceptable skin tolerability. Phase 1 human trials are expected to begin in Q2 2025

Therapeutic areas: PulmonologyCardiovascular
Modalities: Small moleculeProdrugTransdermal patch drug delivery system
Industry: Biotech

Partnerships

United Therapeutics (strategic partnership in PAH therapies)

Beyond the preview

Go deeper on Corsair Management.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corsair Management.

Explore the full profile